Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | S100A4 | P26447 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10819272 | 0.81 | MEN1 (0.44) | KMT2AMEN1S100A4POLBMAPT | |
| SCHEMBL22845855 | 0.78 | GSK3B (0.42) | KMT2AMEN1S100A4POLBMAPT | |
| SCHEMBL8365427 | 0.75 | ALDH1A1 (0.58) | KMT2AMEN1S100A4POLBMAPT | |
| SCHEMBL10287951 | 0.75 | MEN1 (0.48) | KMT2AMEN1S100A4POLBMAPT | |
| SCHEMBL8832034 | 0.72 | HTR2A (0.58) | KMT2ACYP1A2MAPK1 | |
| SCHEMBL7915228 | 0.71 | MEN1 (0.48) | KMT2AMEN1S100A4POLBMAPT | |
| SCHEMBL9055148 | 0.71 | MAPT (0.52) | KMT2AMEN1S100A4POLBMAPT | |
| SCHEMBL6290148 | 0.71 | MEN1 (0.44) | KMT2AMEN1S100A4POLBMAPT | |
| SCHEMBL25817086 | 0.71 | KMT2A (0.44) | KMT2AMEN1S100A4POLBMAPT | |
| SCHEMBL18395286 | 0.70 | KMT2A (0.55) | KMT2AMEN1S100A4POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809010-B2 | Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases | PROBIODRUG AG (DE) | 2014-08-19 | — | — | US | disclosed |
| US-8647834-B2 | Screening method for enzyme inhibitors | PROBIODRUG AG (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8338120-B2 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor such as 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders; dementia | PROBIODRUG AG (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120183974-A1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120184518-A1 | METHODS OF TREATING OR PREVENTING AN INFLAMMATORY DISEASE OR CONDITION USING GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2012-07-19 | — | — | US | disclosed |
| US-8129160-B2 | Method of screening for inhibitors of glutaminyl cyclase activity | PROBIODRUG AG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | 92229129 QUEBEC INC. (CA) | 2010-12-16 | — | — | US | disclosed |
| US-7732162-B2 | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases | PROBIODRUG AG (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20100040575-A1 | USE OF INHIBITORS OF GLUTAMINYL CYCLASE AND GLUTAMATE CYCLASE FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | PROBIODRUG AG (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100009337-A1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20090068699-A1 | USE OF GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20080249083-A1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | disclosed |
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | GLS, QPCT, GLS2 | KMT2A 3778/4885MEN1 4487/4885S100A4 3409/4885 |
| US-20100040575-A1 | USE OF INHIBITORS OF GLUTAMINYL CYCLASE AND GLUTAMATE CYCLASE FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | QPCT, GLS, GLUL | KMT2A 3450/4885MEN1 4477/4885S100A4 3885/4885 |
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | MGAM, BPGM, PPME1 | KMT2A 2187/4885MEN1 3104/4885S100A4 4648/4885 |
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | VCAM1, AOC2, AOC1 | KMT2A 2165/4885MEN1 4135/4885S100A4 715/4885 |
| US-20090068699-A1 | USE OF GLUTAMINYL CYCLASE INHIBITORS | QPCT, GGCT, GLS | KMT2A 1721/4885MEN1 267/4885S100A4 4441/4885 |
| US-20120184518-A1 | METHODS OF TREATING OR PREVENTING AN INFLAMMATORY DISEASE OR CONDITION USING GLUTAMINYL CYCLASE INHIBITORS | QPCT, GGCT, GLUL | KMT2A 2153/4885MEN1 1356/4885S100A4 2862/4885 |
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS2, GLS, GLUL | KMT2A 591/4885MEN1 1003/4885S100A4 4713/4885 |
| US-20080249083-A1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | QPCT, QPCTL, GLUL | KMT2A 1699/4885MEN1 3802/4885S100A4 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.